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data in man. Since the publication of the first pharmaco-EEG 
guidelines in 1982, technical and data processing methods 
have advanced steadily, thus enhancing data quality and ex-
panding the palette of tools available to investigate the ac-
tion of drugs on the central nervous system (CNS), determine 
the pharmacokinetic and pharmacodynamic properties of 
novel therapeutics and evaluate the CNS penetration or tox-
icity of compounds. However, a review of the literature re-
veals inconsistent operating procedures from one study to 
another. While this fact does not invalidate results per se, the 
lack of standardisation constitutes a regrettable shortcom-
ing, especially in the context of drug development pro-
grammes. Moreover, this shortcoming hampers reliable 
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 Abstract 
 The International Pharmaco-EEG Society (IPEG) presents
updated guidelines summarising the requirements for the 
recording and computerised evaluation of pharmaco-EEG 
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comparisons between outcomes of studies from different 
laboratories and hence also prevents pooling of data which 
is a requirement for sufficiently powering the validation of 
novel analytical algorithms and EEG-based biomarkers. The 
present updated guidelines reflect the consensus of a glob-
al panel of EEG experts and are intended to assist investiga-
tors using pharmaco-EEG in clinical research, by providing 
clear and concise recommendations and thereby enabling 
standardisation of methodology and facilitating compara-
bility of data across laboratories. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Pharmaco-electroencephalography (pharmaco-EEG) 
concerns the description and the quantitative analysis of 
the effects of substances on the central nervous system 
(CNS) by means of neurophysiological and electrophysi-
ological methods used within the framework of clinical 
and experimental pharmacology, neurotoxicology, thera-
peutic research and associated disciplines. For the re-
mainder of this article, the acronym pharmaco-EEG 
strictly refers to human quantitative electroencephalog-
raphy (QEEG) in the context of drug testing. Separate 
guidelines for pharmaco-sleep studies in man are in 
preparation for publication by the International Pharma-
co-EEG Society (IPEG). Evoked potentials (EPs)/event-
related potentials (ERPs), in which the time-locked EEG 
signal resulting from a specific event is examined, repre-
sent another area of study and will be the subject of ded-
icated guidelines.
 In the 80s and early 90s, several guidelines were pub-
lished with the goal to standardise the acquisition and 
processing of data collected in pharmaco-EEG studies 
 [1–3] or to provide procedural recommendations for the 
recording and quantitative analysis of EEG activity in re-
search contexts  [4] .
 The initial pharmaco-EEG guidelines were comple-
mented in 1995 by another guideline paper providing the 
framework to build standard operating procedures 
(SOPs), identifying the key components and minimum 
requirements for data acquisition, amplification and fil-
tering, the validation of hardware and software, artefact 
treatment and fast Fourier analysis  [5] . This framework 
constituted the basis for setting up laboratory-specific 
SOPs. This attempt was driven by the mandatory need for 
compliance to good clinical practice, an international 
quality standard launched by the International Confer-
ence on Harmonisation (ICH), an international body de-
fining standards that governments can transpose into 
regulations for the registration of pharmaceuticals and 
for the conduct of clinical trials involving human sub-
jects. Good clinical practice requires SOPs to be available 
to document all methods and procedures in use during 
drug development.
 In parallel, several organisations published recom-
mendations and guidelines for the use of EEG in various 
clinical fields  [6–8] in an effort to improve standardisa-
tion and facilitate the proper utilisation of the technique 
in clinical practice.
 EEG is a non-invasive method which directly reveals 
the spontaneous synchronised postsynaptic neuronal 
activity of the human cortex with high temporal resolu-
tion. While EEG parameters are among the biomarkers 
with the highest heritability  [9–12] , they show at the 
same time a very high sensitivity to changes in both en-
vironment and internal states (state-modulated traits). 
The sensitivity to such factors, which are extraneous to 
the objective of many studies, means that a high degree 
of quality control and detailed SOPs are required in or-
der to decrease the effect of confounders in the analysis 
of the data.
 While pharmaco-EEG has demonstrated its value in 
the development of CNS-active compounds in many in-
stances, and while validated quantitative methods have 
been available for a long time to study the effects of drugs 
on brain functions in patients and volunteers  [13] , there 
is still reluctance to apply this method in large-scale clin-
ical trials or for pivotal drug studies. There are a number 
of reasons contributing to this situation:
 (1) While there is evidence indicating the putative utility 
and validity of EEG as a biomarker relevant to a range 
of drug classes covering several therapeutic indica-
tions, it has not yet been generally accepted as such. 
Further, the translatability of pharmaco-EEG signa-
tures is not universal across the spectrum of CNS-ac-
tive drugs, but depends on the pharmacological mech-
anism and the preclinical species used. Hence its use 
as a translational biomarker for the preclinical screen-
ing of compounds and the development of new drugs 
requires careful interpretation  [14] . 
 (2) Despite the fact that pharmaco-EEG has been used in 
research laboratories for several decades now  [15, 16] , 
operating procedures have not yet been standardised 
to an extent facilitating reliable comparison of datasets 
and results across units, making it difficult (or even 
impossible) to share datasets between sites or to pool 
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 (3) This lack of standardisation constitutes a difficult ob-
stacle for the design and interpretation of clinical trials 
due to the difficulties in comparing results across the 
literature. 
 (4) The large inter-individual variability observed in EEG 
records, some of which may be attributable to the lack 
of standardisation, can be compensated by increasing 
the sample size, provided that the behavioural and 
awareness state of the subjects is tightly controlled. 
However, trial costs quickly become prohibitive as the 
sample size increases and hence improvements in 
standardisation which enable sample size reductions 
will make routine application more attractive. Despite 
this, EEG is still one of the cheapest of the various 
methods that can be used as a window into the brain’s 
activity, and also has the advantage that it can feasibly 
be integrated into first-in-human studies. 
 (5) For a long time, the amount of data generated by re-
cording EEG signals from multiple electrodes quickly 
overwhelmed the storage capacity of computers and 
the processing techniques were constrained by CPU 
power. These limitations have now disappeared as a 
consequence of vastly increased computing power and 
storage capacities. 
 In this context, one of the crucial steps is to enhance 
the standardisation of the operating procedures, not only 
to improve the ability to compare EEG data and results 
generated in different laboratories by reducing variance 
but also to facilitate the creation of a centralised reposi-
tory where a large number of records could be stored and 
shared. Such a repository would enable the following en-
deavours:
 (1) Constitute reference datasets (i.e. both the raw EEG 
signals recorded against a unipolar reference and the 
derived parameters) obtained under standardised 
conditions from different studies using various drugs 
(with emphasis on reference drugs and including pla-
cebo) and study populations (healthy volunteers and 
various patient populations) under standardised be-
havioural conditions, enabling comparative analyses. 
 (2) Identify EEG parameters and properties that could be 
exploited as potential (translatable) biomarkers and 
quantify their validity on large populations. 
 (3) Facilitate the transition of novel compounds from pre-
clinical to clinical research and development pro-
grams by enabling the early comparison of results ob-
tained in preclinical screening and early clinical ex-
periments, thereby improving the decision-making 
process as well as de-risking and accelerating the de-
velopment of new CNS-active compounds. 
 Pharmaco-EEG Studies 
 Fundamentals 
 Pharmaco-EEG studies are applicable when there are 
indications that a substance may have an effect on the 
CNS at therapeutic or pharmacologically relevant dose 
levels. Pharmaco-EEG studies are indicated in all phases 
of clinical research and may answer questions in clinical 
pharmacology as well as in therapeutic research. It is the 
consistency and nature of the empirical observations cap-
tured by the pharmaco-EEG method, particularly in the 
realm of clinical psychopharmacology, which have estab-
lished this technique as a suitable means for a complete 
quantitative description of the effect of a drug on the 
function of the brain in humans  [17, 18] . Pharmaco-EEG 
data can be exploited to classify psychotropic substances 
 [19, 20] and to assess drug-drug interactions or to moni-
tor side effects and toxicity  [21] . The use of quantitative 
methods for data reduction and statistical analysis pro-
vides quantitative descriptions of the direct and indirect 
effects of active compounds on brain functions  [22] hence 
generating pharmacodynamic (PD) outcome measures 
which, along with separate pharmacokinetic (PK) data 
(e.g. drug concentration from blood samples), can be 
used to study the PK-PD relationship  [23–25] .
 Pharmaco-EEG studies need to be designed in accor-
dance with the objectives of the study (including placebo 
control and/or reference drug and test-retest design 
when indicated, and always keeping the behavioural and 
awareness state of the subjects under well-controlled 
standardised conditions) and require appropriate statis-
tical methods adapted to the study design and the inves-
tigated hypotheses. Dependent upon the study objec-
tives, either patients and/or normal volunteers may be 
examined. Although a given psychotropic drug tends to 
produce similar and replicable EEG profile changes in 
different populations at the group level, per-subject dif-
ferences in EEG response profiles have also been shown 
to be a useful indicator of the biological variability and 
therapeutic potency of a compound. Less potent psycho-
tropic drugs often exhibit higher biological variability 
(as seen in individual EEG response profiles), while more 
therapeutically potent compounds (i.e. with low biologi-
cal variability) generally produce very similar EEG pro-
file changes in the majority of subjects tested  [26] . In pa-
tient populations, clinical response to drugs has shown 
to be a source of variation with different patterns ob-
served in responders versus non-responders  [27, 28] . 
This illustrates the potential utility of EEG for patient 
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to certain drug therapies, thus facilitating a personalised 
medicine approach.
 All clinical trial programmes must follow the ICH 
guidelines aimed at ‘ensuring that good quality, safe and 
effective medicines are developed and registered in the 
most efficient and cost-effective manner. These activities 
are pursued in the interest of the consumer and public 
health, to prevent unnecessary duplication of clinical tri-
als in humans and to minimize the use of animal testing 
without compromising the regulatory obligations of safe-
ty and effectiveness.’ The ICH guidelines cover a broad 
range of activities related to drug development  [29, 30] .
 In addition, the responsible investigator should: (a) be 
acquainted with the literature and techniques of EEG 
data processing which are the basis for the interpretation 
of the results; (b) understand the range of normal and 
abnormal variability of the neurophysiological methods 
used, and (c) be responsible for the planning, organisa-
tion and execution of the study.
 Subjects 
 Due to the broad spectrum of neurophysiological do-
mains where pharmaco-EEG studies are applicable, it is 
not possible to provide an all-inclusive standard for sub-
ject-related data which should be collected in pharmaco-
EEG trials. The type of subject data to be collected may 
depend upon the objectives, targeted population, pathol-
ogy (by patients) and other attributes of a specific trial. 
 The following factors should be considered when com-
piling inclusion and exclusion criteria for a particular 
study and documented routinely: demographic data (age, 
gender, handedness and socioeconomic status); medical 
history [state of health, prior illnesses, presence of any 
metabolic syndrome, hyperglycaemia or thyroid disor-
der, use of drugs (including medication and recreational 
substances, particularly cannabis), sleep quality and be-
haviour, and EEG characteristics]; psychiatric history 
(DSM or ICD diagnoses), and use of tobacco, coffee, tea, 
energy drinks and alcohol (before and during the days of 
examination). If relevant, more personal characteristics 
are to be filed: emotional lability, neuroticism, extraver-
sion/introversion; important psycho-physiological attri-
butes such as emotional state (anxiety or fatigue), reac-
tion to stress, bladder or bowel problems and menstrual 
cycle, for example. Where possible, standardised rating 
scales should be used to quantify characteristics and sub-
jective descriptors should be avoided.
 Table 1 summarises the set of subject metadata to be 
recorded in pharmaco-EEG trials.
 Given the profound effect of nicotine, caffeine and al-
cohol consumption on the EEG signal, it is generally rec-
ommended to restrict the use of these products in clinical 
EEG trials, for instance by excluding subjects if they meet 
any of the following conditions within the previous 6 
months:
 • History of regular alcohol consumption exceeding 2–3 
units/day for females and 3–4 units/day for males  [31] 
 • History of regular use of tobacco or nicotine-contain-
ing products exceeding the equivalent of 5 cigarettes 
per day 
 • History of regular consumption of caffeine exceeding 
the equivalent of 4 cups of coffee per day, a level that 
approximates health-related criteria  [32] 
 In addition, subjects should refrain from alcohol and 
caffeine for at least 24 h, and from tobacco or nicotine 
products for at least 4 h (preferably 8 h) prior to an EEG 
recording.
 Stricter exclusion criteria or restrictions may be ap-
plied on a study-by-study basis where required.
 Phenotyping and/or genotyping of the participants is 
acquiring increasing importance for safety and PK rea-
sons; since drugs can be primarily metabolized through 
specific cytochrome P 450 (CYP) isoenzymes, metabolic 
status could be defined accordingly in order to avoid po-
tential accumulation/fast elimination during the wash-
out phase, for example. If a drug is known to be subject 
to a major genetic polymorphism, studies could be per-
formed in panels of participants of known phenotype or 
genotype for the polymorphism in question.
 In addition, genotyping is becoming relevant for the 
EEG itself: it has been demonstrated that a low/high nat-
ural   rhythm can influence the interpretation of the 
Demographics Age, gender, handedness
Medical history State of health, prior or current illnesses, psychiatric history
Screening EEG Abnormalities, high/low  power
Medication status Current use of drugs, use of drugs in the past 4 weeks
Use of alcohol, tobacco, illicit drugs
Table 1. Minimum set of subject 
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EEG response to drugs  [33] , and studies of twins conclude 
that the high inter-individual variability in   power and 
  peak frequency is largely genetically determined  [9–12] . 
Today, the best candidate is a gene encoding catechol- O -
methyltransferase. According to a recent study  [34] , the 
Val 158 Met polymorphism of the enzyme is highly predic-
tive of individual   activity, with the Val allele carriers 
displaying lower   peak frequency and lower   activity 
compared to the Met allele carriers. If this variability is 
likely to have an effect on a particular study, then suitable 
subjects could be selected either by genotyping or by 
screening for low/high EEG   rhythm. Alternatively, ge-
notyping data could be collected for post hoc analysis.
 Pharmaco-EEG – Data Acquisition 
 Digital Recording 
 Digitising is the conversion of an analogue (continu-
ous) signal into a digital (discrete) representation (i.e. a 
sequence of numbers). Analogue-to-digital (A/D) con-
verters usually have a resolution of 16 bits, meaning that 
the analogue amplitude of each discrete point is repre-
sented by a value ranging from 0 to 65,535 (0 to 2 16  – 1). 
The sampling rate (T S ) corresponds to the time interval 
between two subsequent points and determines the reso-
lution in time. The sampling frequency (F S ) expresses the 
number of samples digitised per second and is the recip-
rocal of the sampling rate (F S = 1/T S ). With a sampling 
frequency of 500 Hz, the resolution in time (  s) corre-
sponds to the sampling rate and is given by the reciprocal 
of the sampling frequency, i.e. 2 ms.
 From a theoretical point of view, the sampling fre-
quency must be at least twice the highest frequency pres-
ent in the signal to be digitised (Nyquist-Shannon sam-
pling theorem). Conversely, frequency components high-
er than half the sampling frequency (also called Nyquist 
frequency, F N = F S /2) must be removed using analogue 
filters before digitising to avoid aliasing effects. Errors 
introduced in the digitised signal by aliasing cannot be 
detected and corrected afterwards. Because of imperfec-
tions in the analogue filters, the sampling frequency is in 
practice at least fourfold the analogue filter (anti-alias-
ing) cut-off frequency.
 From a practical point of view, the following applies 
for pharmaco-EEG studies: Sampling frequency must be 
at least 500 Hz (i.e. 500 samples per second) and be a mul-
tiple of 50 or 64 [e.g. 500 or 512 Hz (currently in neuro-
cognitive studies and in epilepsy, EEGs are being record-
ed with a wider frequency band to allow the study of high 
  band components or, more generally, high frequency 
oscillations; in this case, sampling has to be at rates  1 2 
kHz. This is discussed in the section on High-Frequency 
(  ) EEG Activity below)]. The A/D converter must have a 
digital resolution of at least 16 bits and resolve changes in 
the EEG below 0.2   V. Prior to sampling, an anti-aliasing 
low-pass filter set at 70 Hz (with a roll-off of at least 12 
dB/octave) must be used and the high-pass filter should 
be set below 0.5 Hz (time constant  1 2 s; recommended 
0.01 Hz). Ideally, digital recordings should be made with 
minimal filtering (as above) and additional filters applied 
post hoc. This enables the effect of the filtering step to be 
evaluated. In particular, the use of a notch filter (50 or 60 
Hz) during recording should be avoided as it can poten-
tially disguise an electrode problem, while the mains 
noise can be eliminated off-line at the data processing 
stage. 
 The electrode impedance (or resistance) should con-
ventionally be maintained below 5 k  . However, modern 
amplifiers with high internal resistances are able to re-
cord at higher scalp impedances (e.g. without using con-
ductive gel). Similarly, MRI compatible EEG caps have 
inbuilt safety resistors that set a minimum impedance of 
around 10 k  . In these cases, higher impedance is accept-
able, but in all cases it is important to balance impedance 
across electrode sites. The preamplifier input impedance 
must be over 100 M  . As the rejection of cross-talk be-
tween channels is important for coherence or other mea-
sures of relationships between electrodes, a cross-talk re-
jection of at least 90 dB is required and better is recom-
mended.
 Comprehensible overviews on technical aspects relat-
ed to the digital recording of EEG signals have been pub-
lished elsewhere and provide additional insight on spe-
cific details  [35–37] .
 Calibration 
 Recording accuracy (how far the sample varies from 
the ‘true’ signal value) is dependent upon system calibra-
tion. The calibration procedure is aimed at testing the 
performance of the entire hardware and must be carried 
out before each measurement. Calibration is also essen-
tial to achieve a reference potential of known voltage 
against the absolute amplitude of the recorded signals. To 
pick up possible time-dependent fluctuations of ampli-
fiers, due to thermic effects for example, it is recommend-
ed to re-check the calibration at the end of each measure-
ment session.
 Nowadays, most EEG machines have internal hard-
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automatically. Verification is made that the same input 
signals (sine waves with known amplitude and frequen-
cy) applied to all channels are present with the same am-
plitude at the output of the amplifiers and are subse-
quently correctly transmitted to the A/D converter. If in-
ternal calibration is not available, then an external device 
should be used to generate stable test waves that are re-
layed through the electrode sockets.
 Ideally, standardised calibration procedures should 
include sine waves of stable amplitude (e.g. 100   V) at two 
different frequency ranges (e.g. at 1 and 10 Hz) whether 
internally generated or from an external source. Verifica-
tion of the calibration signal should be performed with 
digital callipers utilising as long a duration of the calibra-
tion signal as possible (e.g. 1 min per frequency). Al-
though no definitive data currently exist on the amount 
of tolerable deviation for pharmaco-EEG signals, a max-
imum acceptable variance of  8 2% in signal amplitude at 
both frequencies is recommended. Between-channel dif-
ferences suggest an amplifier imbalance and channels 
with  1 8 2% variance should be eliminated from analysis.
 Electrode Positions 
 While demonstration has been made in the past that 
it is possible to trace the effects of specific compounds 
with a limited number of electrodes (e.g. using the bipolar 
fronto-central and occipito-temporal derivations, F z -C z 
and O z -T 6 ), it is no-longer state-of-the-art and inappro-
priate for advanced investigations. Instead, a configura-
tion of 21 electrodes placed according to the internation-
al 10–20 system  [38] is the recommended minimal elec-
trode configuration. If additional EEG electrodes are 
used (e.g. for mapping or localisation studies), then the 
international extended 10–20 electrode placement sys-
tem (also known as 10% system  [39–41] ) should be 
utilised. The nomenclature of the electrodes must follow 
these standards.
 Many laboratories use electrode caps (as opposed to 
measuring individual electrode positions) for ease of ap-
plication of dense electrode arrays. However, cap elec-
trode positions only approximate the 10–20 locations and 
are rarely measured accurately. It is important to ensure 
that the electrode location does not deviate from the stan-
dard when using caps.
 As a matter of principle, recording against one refer-
ence electrode is recommended (e.g. against C z , A 1 and 
A 2 ) or the arithmetic mean of A 1 and A 2 [(A 1 + A 2 )/2] (i.e. 
a mathematically generated ‘linked-ear’ or ‘linked-mas-
toid’ reference). Without resistors between them, two 
linked electrodes (e.g. A 1 with A 2 ) connect two brain re-
gions, thereby changing the electrical potential distribu-
tion over the scalp. Hence, although the resulting distor-
tion of potential may be negligible in many or even most 
cases  [42] , physically linking the electrodes is not recom-
mended. A linked reference may also be problematic if 
the impedance of one or other electrode varies differen-
tially during a recording (for example if one of the elec-
trodes becomes dislodged). The data must be stored in a 
format permitting conversion from the recording refer-
ence to any other reference (common average reference, 
current source derivation or other channels as reference, 
for example). Active electrode systems can be used in 
pharmaco-EEG studies provided that active electrodes 
would not distort any frequency components in the fre-
quency range 0.05–40 Hz.
 In addition, EOG (electrooculography) must be re-
corded (vertical and horizontal, bipolar) to aid in identi-
fying artefacts and to correct off line the interference cap-
tured in the EEG using appropriate data processing algo-
rithms. The recording of both ECG (electrocardiography) 
for assessment of the activity of the autonomous nervous 
system and EMG (electromyography) as additional mark-
er for vigilance stages or artefacts is recommended. The 
recording of other vital parameters, such as blood pres-
sure and respiration, is optional.
 Environmental Conditions 
 There are many environmental factors affecting the 
function and activity of the CNS and, as a result, also af-
fecting neurophysiologic readouts of brain activity. It is 
therefore necessary to control these factors to the best 
possible extent. If deviations from normal, pre-existing 
or pre-defined conditions are observed, then these should 
be recorded as metadata. In clinical trials, it is manda-
tory to document the degree to which these factors have 
been used as inclusion and exclusion criteria.
 Adaptation.  EEG measurements are subject and sensi-
tive to adaptation effects. Consequently, at least one pre-
examination EEG recording (apart from the screening 
EEG) should ideally be performed on a separate day to 
carry out one (or several) blank or habituation 
measurement(s). Such a procedure allows the subject to 
become familiar with the environment, apparatus and re-
cording protocol. When this additional subject visit is not 
feasible, then a period of acclimation should be included 
in the protocol on the study day itself before the actual 
recording session is started.
 Room.  The recording should occur in a separate, 
sound-attenuated room with constant light (approxi-
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and normal humidity conditions. Intermittent disturb-
ing events must be avoided. Random and undefined in-
teractions between the subject and the staff during the 
recording (as for changing the electrode placement or 
posture, or giving additional instructions or stimulation) 
should be limited and documented. Typically, clinical 
neurophysiology studies are carried out with the subject 
sitting in a half-reclined position to reduce neck muscle 
tension and with constant dimmed light (approximately 
40 lx) and this is recommended in many cases. However, 
these conditions are not amenable to the presentation of 
a task and so resting data acquired in this way will not be 
suitable for comparison with subsequent task-related re-
cordings forming part of the same study. Hence in studies 
involving both resting and task-related recordings, it is 
recommended that resting recordings be made in a situ-
ation that exactly replicates the recording conditions to 
be used when engaged in tasks (i.e. the subjects should be 
comfortably seated in a suitably supportive high-backed 
chair in an upright position). The ambient light level 
should be maintained at a similar level during resting and 
task-related recordings.
 Time of Recording.  Recording periods should be com-
pleted at the same time of the day and under the same 
conditions. If possible, having documentation of a sub-
ject’s wake and sleep history (e.g. around 1 week of con-
sistent bed- and rise-time) is advisable to assist in recog-
nising circadian influences on the EEG (subjects with 
highly disrupted sleep should be carefully evaluated and 
potentially excluded from the study). Whenever possible, 
the recording should preferably occur in the morning 
(between 9: 00 and 13: 00 h) to avoid interference with 
meal times and postprandial vigilance fluctuations. This 
aspect is to be taken into consideration for the design of 
studies with repeated measurements following drug in-
take (e.g. at baseline and 1, 2, 4 and 8 h after medication). 
Also the type of food (breakfast and lunch) must be care-
fully selected.
 Recording Conditions 
 For the purpose of standardisation and to ensure that 
results obtained in one laboratory can be compared with 
results obtained in another, pharmaco-EEG studies 
should be recorded under one or more of the following 
conditions:
 (1) Vigilance-controlled EEG for 5 min (RT). During 
this recording session, the subjects must have their eyes 
open and the vigilance level should be controlled by a 
simple continuous performance task (e.g. creating a story 
out of given words or solving simple arithmetic prob-
lems), which incorporates a fixation point to minimise 
eye movement artefacts. The purpose is to stabilise the 
vigilance to a relatively narrowly defined level by means 
of the continuous mental exercise. The EEG should be 
monitored online by an EEG technician and short exter-
nal interventions for vigilance stimulation are permissi-
ble if a decrease in vigilance is observed, for instance in 
case of intrusion of slow-wave activity in the EEG. How-
ever, the EEG segments in which the interventions oc-
curred are labelled as artefacts and are excluded from the 
evaluation.
 (2) Resting EEG with closed eyes for 5 to 15 min (RSc). 
During this session, the EEG is recorded with closed eyes 
and fluctuations of vigilance are permitted without any 
restriction, the purpose of this recording condition being 
to examine the variations in vigilance over time. It is es-
sential that the instructions should be explicit, such as ‘Sit 
quietly and keep your eyes closed; there is no task to com-
plete, just relax!’ Limited external interventions should 
take place during the session and used only when neces-
sary to help maintain consistency of state (e.g. eyes open-
ing). Drowsiness EEG patterns or falling asleep are not a 
reason to intervene. While sessions of 5 min yielding a 
minimum of 2-min artefact-free signal are sufficient to 
quantify EEG activity and demonstrate pharmacological 
effects on spectral parameters  [43] , the recording may be 
extended to 15 min to assess the regulation of vigilance 
(‘CNS arousal’) and wakefulness, and to quantify drug-
induced changes in these parameters (e.g. sleepiness) 
 [44] .
 (3) Resting EEG with open and closed eyes for 5 min in 
each eye state (RS co ). Recordings of this type employ al-
ternate periods with eyes open and closed of 1-min dura-
tion each in response to commands from the technician. 
Subjects should face a featureless wall in order to stan-
dardise the visual environment and reduce the effect of 
eye movements on the EEG during periods with open 
eyes. No additional vigilance control procedure should be 
used; in particular, fixation is not recommended as this 
in itself constitutes a task. Data in each of the two states 
should be separated prior to processing and the EEG ac-
tivity analysed separately for segments with open and 
closed eyes.
 Important Comments: 
 • The task to be used during the vigilance-controlled 
condition has deliberately not been tightly defined in 
order to encompass the range of currently accepted 
practice. One particular variation is to use a visual 
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which has the benefit of also providing a measure of 
performance whereby epochs surrounding stimulus 
presentation and motor response or outside preset 
limits of ‘normal’ reaction time can be excluded from 
the analysis. There are also other accepted procedures 
for maintaining vigilance during EEG recording, in-
cluding the use of a device which is sensitive to muscle 
relaxation. However, it is important to note that the 
results cannot be readily compared when different 
tasks or vigilance control methods are used as system-
atic differences in both the topography and frequency 
composition of the resulting EEG signals are to be ex-
pected. Hence, the method used must always be clear-
ly described alongside the results. 
 • Continuous video recording synchronised with the 
EEG is recommended. 
 • It may not be possible to fully adhere to the standard 
procedures in cases where patients are uncooperative 
or unable to follow instructions (e.g. psychotic or se-
verely demented patients). Any deviations from the 
standard must be clearly stated alongside the presenta-
tion of the results. 
 • EEG recording should always take place prior to ad-
ditional testing (e.g. cognitive paradigms), since vigi-
lance might be decreased after exhausting or time-
consuming tests. 
 • Since the brain activity indicated by the EEG depends 
strongly on the present level of vigilance  [45] , care has 
to be taken that drug effects on vigilance regulation 
(e.g. more rapid decline to lower vigilance stages with 
sedating drugs) are separated from drug effects on 
EEG activity within the same vigilance level (e.g. in-
crease in   frequency). 
 • With measures such as connectivity, phase and coher-
ence, there is evidence that more data are necessary to 
converge to stable, reliable estimates, and hence the 
recording duration for any of the conditions may be 
extended if required to meet the objectives of the study. 
 Artefacts 
 Artefact identification and elimination is crucial for 
the proper quantitative analysis of EEG records. With op-
timal recording conditions, artefacts are only accidental 
and appear infrequently. Artefacts can have various phys-
iological origins (ocular, cardiac, muscular, behavioural, 
sweating and respiratory) and can be identified and/or 
eliminated either on line during the recording or off line. 
Special care should be taken in those studies where high-
er frequency bands (i.e.   and   ) are of interest since the 
EEG signals may be contaminated by muscle activity.
 Automated EOG artefact rejection is possible using 
appropriate algorithms  [46–48] . However, when comput-
erised algorithms are used, a semi-automatic procedure 
that includes additional visual inspection is recommend-
ed. Even new approaches such as the independent com-
ponent analysis (ICA) used for the detection of eye move-
ment or muscle artefacts  [49] should be applied with cau-
tion. The risk of excluding components with mixed 
neurophysiological information of brain activity and ar-
tefacts should be minimised by careful inspection of top-
ographic maps of the components and by using an appro-
priate number of components (equal to the number of 
channels of the input matrix).
 Should the investigator doubt the validity of the pro-
cedure either because of the large percentage of EEG seg-
ments containing artefacts or because the kind of arte-
facts could be confused with the treatment effect, then a 
comparative biometrical evaluation and assessment of 
the artefact-free and complete data should follow.
 Minimum Requirements 
 Table 2 summarises the minimum requirements for 
the recording of pharmaco-EEG studies.
 Pharmaco-EEG – Data Processing 
 Representation in the Time Domain 
 In the time domain, the variations in potential after 
amplification are displayed as a function of time and sig-
nals are usually denoted by a function s(t) [or s(k T S ) 
(with k = 1…N) in its digital form]. The representation in 
the time domain is used for the visual inspection of EEG 
curves and for the evaluation of EEG activity resulting 
from external sensory stimulation for which the position 
in time is relative to the time point at which a stimulus 
occurs. Thus, time is considered as a variable of the ob-
served phenomenon. The detection of patterns or tran-
sient activities in the EEG usually relies on processing 
algorithms operating in the time domain.
 Representation in the Frequency Domain 
 The transformation of a signal s(t) into the frequency 
domain using the fast Fourier transformation (FFT) im-
plicitly assumes that s(t) can be split up as a finite sum of 
weighted sinusoidal waveforms [denoted as s(f)]. The 
number of sinusoidal waveforms is dependent upon the 
window size (i.e. the number of points of the input signal) 
subjected to FFT. The resulting graphical representation 
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Table 2.  Minimum requirements for the recording of pharmaco-EEG studies
EEG recording 
equipment
Sampling rate ≥500 Hz
A/D conversion ≥16 bits
High-pass filtering ≤0.5 Hz (0.01 Hz recommended)
Low-pass filtering 70 Hz (roll-off of at least 12 dB/octave)
Notch filter Usage avoided; otherwise 50 or 60 Hz (dependent on the power supply frequency)
Pre-amplifier impedance ≥100 M  at 50 Hz
Common mode rejection ≥90 dB
Electrodes Electrode impedance Balanced impedance across all electrode sites
Number and placement At least 21 electrodes placed according to the 10–20 system or the extended
10–20 system (10% system) in case >21 electrodes are used
Type Ag/AgCl or equivalent in terms of electrode drift and DC resistance
Montage Monopolar against a common reference
Reference Should be modifiable post hoc, (Cz, A1, A2, average mastoids)
Ground AFz






Adaptation It is recommended to make the subject familiar with the recording conditions and 
procedures during a separate recording session
Recording environment Sound-attenuated room
Constant dimmed light (approximately 40 lx) 
or light level defined by the computer monitor used for task presentation
Constant room temperature: 20–23°C (68–73°F)
Any major disturbances should be logged
Subject in a (semi-)reclined comfortable position or in an upright position facing a 
computer monitor (for studies that also include a task)
Design Double-blind placebo-controlled cross-over design is recommended for acute studies 
in healthy subjects
For multiple dose and patient studies, the design should be adapted according to the 
objectives
Recording time points Baseline and a number of post-drug recording time points to be driven by drug PK; at 
least one time point around Tmax plus at least 3 time points covering the decline in the 
PK curve (usually multiples – e.g. 1, 2, 4 and 8 h)
If Thalf ≥12 h, then a 24-hour overnight time point should be considered
Time of day Preferably in the morning
Cross-over repeat tests should be done at the same clock time and under the same 
conditions
Recording conditions RT (5 min vigilance controlled, eyes open)
RSc (5- to 15-min resting condition, eyes closed)
RSco (10-min resting with alternate eyes open and eyes closed)
Storage
conditions
Local storage The proprietary format of each EEG recording equipment
Export/import format European data format ‘plus’ [see ref. 50 for details]
Signals Raw data without transformation
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depicted by peaks in the frequency domain. This kind of 
display is generally used for the evaluation of spontane-
ous EEG activity for which the position in time of events 
has no direct relevance.
 The FFT (as an orthogonal transformation) is essen-
tially a mathematical operation performed on time series 
data which does not alter the information content of the 
signal. Neither is any assumption made regarding the na-
ture of the data nor any interpretation implied. Within 
the limitations of computational accuracy, the full revers-
ibility of the transformation is implicit and given only as 
long as numbers are retained in their complex form and 
not averaged.
 The resolution in the frequency domain depends upon 
the sampling frequency (F S ) and the number (N) of sam-
pling points (size of the signal window) subjected to FFT. 
This resolution (denoted here as F) is given by the ratio 
(F = F S /N). Accordingly, the longer the signal window 
(N), the better the resolution of the frequency content.
 When considering the results of an FFT applied to a 
signal window of N = 2,048 points (a number chosen be-
cause it corresponds to 2 11 and facilitates a rounded-off 
length) with F S = 512 Hz, then F = 0.25 Hz, which means 
that the frequency analysis can resolve 0.25 Hz (that is 
resolve 10.25 vs. 10.50 Hz directly). In this particular 
case, the signal window (called epoch) will have a length 
of 4 s.
 To reduce the broadband artefact, known as leakage, 
the signal window must be tapered toward zero at their 
initial and final data points (this tapering is usually done 
using a windowing function). When the FFT is applied 
on sequential epochs, then discarding a proportion of the 
signal through windowing can lead to differences in 
spectra depending on the starting point of the epoch se-
ries. An alternative that results in a spectrum less sensi-
tive to the starting point is to use partially overlapping 
epochs so that all data are represented.
 Although computer-based analysis of scalp-recorded 
signals for pharmaco-EEG profiling has utilised a wide 
range of quantitative techniques, spectral analysis via 
FFT is currently the most common method of choice for 
the parameterisation of pharmaco-EEG studies.
 Non-Stationarity 
 Many signals, including EEG, are non-stationary, 
which means that they have a time-varying frequency 
spectrum, although they can be considered locally sta-
tionary over short segments in which the parameters of 
interest vary minimally.
 In practice, the choice of the segment length is a trade-
off between frequency resolution (which suggests a longer 
epoch) and ensuring quasi-stationarity (which suggests a 
shorter epoch). For the pharmaco-EEG, epochs of 2- to 
10-second duration are used.
 Spectral Analysis 
 The traditional parameterisation of pharmaco-EEG 
activity is largely based on spectral analysis. To this end, 
the recorded signals are divided into epochs (2–10 s) 
which are subjected to spectral analysis using FFT. This 
transformation in the frequency domain and subsequent 
computation of the power spectrum allows a first data 
reduction.
 The second step of data reduction consists in the extrac-
tion of spectral parameters. The frequency range is subdi-
vided into frequency bands, and the spectral performance 
(area under the curve) is computed for each of them (ex-
pressed in   V/Hz; square root of absolute power) or using 
another transformation (e.g. the natural logarithm of ab-






F 1.5 to <6.0 V/Hz
	F 6.0 to <8.5 V/Hz
1
F 8.5 to <10.5 V/Hz
2
F 10.5 to <12.5 V/Hz
1
F 12.5 to <18.5 V/Hz
2
F 18.5 to <21.0 V/Hz
3
F 21.0 to <30.0 V/Hz
Total power 1.5 to <30.0 V/Hz
 30.0 to <40.0 V/Hz
Dominant frequency 6.0 to <12.5 Hz
ASI 1F + 2F
  F + 	F
%




T he  slow-wave index (ASI) is defined as the ratio between  
activity and the sum of the activity in the  and 	 frequency rang-
es [54]. The 	/ ratio (TBR) expresses the ratio between 	 activity 
and the activity in the two  frequency ranges. The  band was 
included at a later stage and definition of additional frequency 
ranges >40.0 Hz is the subject of further work [see the section on 
High-Frequency () EEG Activity].
FRefers to the factorial analysis used to define the ranges be-
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solute power) to better meet the assumption of normal dis-
tribution  [51–53] . The transformation should preferably be 
carried out prior to any other manipulations, such as aver-
aging spectral parameters across several epochs.
 Table 3 provides a summary of the frequency ranges 
to be used in pharmaco-EEG studies. These frequency 
bands were defined on the basis of factorial analysis of 
EEG records  [55–57] and thereby constitute a very robust 
framework. It does not mean that other frequency ranges 
shall not be used for specific purposes  [58] . However, to 
ensure that the results of a study can be compared with 
others published and therefore can provide useful refer-
ence material for other scientists, publications should al-
ways report the results obtained for this standard con-
figuration (beside others if appropriate).
 Absolute spectral EEG values are recommended as the 
primary outcome measures (endpoints) in the pharmaco-
EEG profiling. Test-retest reliability investigations have 
shown that intra-individual EEG spectral measures can 
be treated as a stable trait  [59] . Additional computed spec-
tral parameters, such as relative values in frequency rang-
es, dominant frequency in the   and   frequency bands, 
peak skewness (asymmetry coefficient), peak kurtosis 
(peak shape) and the activity ratio between different fre-
quency bands, should be interpreted in the light of abso-
lute values  [60] . These derived parameters may provide 
additional insight for the interpretation of the data.
 Pharmaco-EEG Brain Mapping 
 Multichannel topography (‘mapping’) is widely used 
to display activity simultaneously recorded from several 
electrodes. Pharmaco-EEG brain mapping is suited to as-
sess the topographical changes induced by CNS-active 
compounds. Usually, the topographical distribution of 
spectral parameters and error probabilities (probability 
mapping) are displayed  [22, 61, 62] . Time-dependent 
changes of EEG activity can be investigated as a function 
of the recording condition or by analysing segments of 
records (e.g. for the evaluation of vigilance fluctuations).
 Several authors have pointed out limitations and dif-
ficulties of the mapping technique which are related to 
reference problems, the influence of spatial artefacts and 
the clinical interpretation of mapping data. In particular, 
spectral brain maps derived from single electrode refer-
ences have the disadvantage of being substantially dis-
torted near the common reference site and are likely to be 
misinterpreted. This problem can be partially avoided by 
using reference-free derivations (e.g. spatial average refer-
ences or current source density derivations; the latter is 
generally preferred)  [63– 65] .
 The main advantage of mapping lies in its ability to 
easily visualise the spatial relationships of EEG data 
among the scalp recording sites, but it must be remem-
bered that the majority (  99%) of the pixels displayed on 
the oval or circle may represent interpolated values, un-
like the CT or MRI structural images upon which they are 
often overlaid, where 100% of the pixels display real data 
values resulting in a spatial resolution of several orders of 
magnitude greater than that of EEG topographic maps 
 [22] . Advanced interpolation algorithms have been devel-
oped to improve the graphical representation of maps and 
the error made by properly chosen algorithms is usually 
small  [66] . Lack of information about electrical activity at 
locations not covered with EEG electrodes needs to be 
taken into account as low spatial sampling may lead to 
spatial aliasing. This problem cannot be solved by inter-
polating spatially under-sampled data, rather by increas-
ing the number of EEG electrodes that would offer com-
paratively short (e.g. 3–5 cm) inter-electrode distances. 
Last, investigators must be sensitive to the fact that vivid 
colour differences can draw their attention but may rep-
resent only subtle differences in data. To minimise such 
effects, it is suggested that colour coding of images should 
be based upon statistical probabilities, clearly indicated in 
the colour scale or legend provided with the maps.
 In the case of coherence assessment, coherence should 
only be measured for data that have been re-referenced so 
that no pairs of electrodes tested for coherence share an 
electrode in common. Further, when comparing coher-
ence in different conditions, the same number of trials 
should be used to calculate coherence in each condition.
 For technical details on EEG brain mapping refer to 
the abundant literature and review papers published to 
date. Guidelines for the topographic analysis of EEGs and 
EPs have been published by the International Federation 
of Clinical Neurophysiology  [63] and recommendations 
for evaluations in the context of pharmacological studies 
have been published by the IPEG  [67] .
 Data Processing Strategies 
 In principle, the selection of trial design, recording 
conditions and duration, number of measurement points 
and approach for data analysis are dependent upon the 
ultimate objectives of the study. Consequently, the strat-
egy selected for the EEG signal processing is to be adapt-
ed to each specific configuration. As the analysis can be 
very versatile, it is therefore not possible to define strict 
guidelines. Nevertheless, it is useful to provide some 
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 In the following and for the purpose of example, it will 
be assumed that the EEG signals are recorded with a sam-
pling frequency of 500 Hz (F S ) and that the spectral pa-
rameters are computed for epochs of 4-second length (i.e. 
2,000 samples), whereby the FFT are computed based on 
2,048 (2 11 ) points, with the individual overlapping epochs 
being tapered digitally toward zero voltage at their initial 
and final 24 data points. This way, 1 min of EEG record-
ing will produce 15 power spectra, each 4-second epoch 
providing a set of spectral parameters ( table 3 ).
 Considering an EEG signal recorded for 5 min under 
RT or under RS c conditions, the 5-min recording is first 
divided into 75 epochs; artefact-marked epochs are elim-
inated, and the sets of spectral parameters are calculated. 
Then, the strategy for data processing involves two steps 
( fig. 1 ):
 (1) For each spectral parameter, the activity over 5 min is 
quantified using the sample mean and its standard de-
viation (the median and its quartiles or the trimean 
can also be used). This procedure is straightforward 
and provides for each measurement point and each 
EEG channel a set of spectral values that can be com-
pared with others. The main drawback of this ap-
proach lies in the fact that it does not allow changes 
that may occur during the 5-min recording to be cap-
tured  [43] , e.g. as a result of a sedative effect. This prob-
lem can be addressed by proceeding with a subsequent 
complementary assessment. 
 (2) The spectral activity at the beginning and at the end 
of the recording are quantified separately and the re-
sults compared. This assessment is particularly useful 
to verify the stability of the recording condition (as 
expected for RT) or to detect time-dependent changes 
(especially for RS c ). 
 Typically, the duration of the recording under RS c is 
extended to up to around 15 min to assess the dynamics 
of vigilance fluctuations. In this case, the vigilance regu-
lation can be explored and vigilance levels assessed over 
the whole duration of the recording session, from relaxed 
wakefulness to sleep onset  [68–70] . When focusing on 
spectral activities only, the recording can be decomposed 
into segments of equal length (e.g. 3 min) and the spectral 
parameters quantified for each segment ( fig. 2 ) using the 
sample mean and standard deviation or other suitable pa-
rameters as described above, following the elimination of 
epochs containing artefacts. Then, the results obtained 
for the segments at the beginning, the middle and the end 
of the recording can be compared to capture time-depen-
dent changes.
 The processing of EEG signals recorded in the resting 
state with alternate periods of RS co requires separating 
the epochs corresponding to the respective eye states 
( fig. 3 ). Off-line treatment of EOG (blink) events occur-
ring in the open-eye segments is mandatory and requires 
particular attention (e.g. using ICA or similar filtering 
techniques). Then, the spectral parameters can be quan-
tified for each eye state separately using the same method 
as for the RT and RS c recording conditions ( fig. 1 ). Also, 
in this case, it is useful to verify the stability of the re-
cording through assessment of any time-dependent 
changes.
 In pharmacological trials aimed at assessing the effect 
of compounds on the CNS and on the EEG in particular, 
the study design as well as the selected recording condi-
tions and related processing strategies will be dependent 
upon the profile of the compound under examination, 
whereby the hypotheses and targeted parameters will be 
defined upfront. Exploratory evaluations, however, may 
require more flexibility, especially when the potential ef-
fects are unknown. When documented and justified, the 
recording duration and the strategy selected for data pro-
cessing can be adjusted if specifically needed for a par-
ticular study. However, such deviations may impede the 
ability to compare results with other studies.
 Pharmaco-EEG – Statistical Analysis 
 The present guideline paper is not intended to discuss 
the statistical aspects of the design and analysis of phar-
maco-EEG studies and especially of PD studies. To this 
end, reference is made to the corresponding IPEG guide-
lines  [71] , which provide a set of recommendations for the 
investigation of the PD characteristics of a compound 
Ⓐ
Ⓑ
10 2 3 4 5
Recording duration (min)
 Fig. 1. Processing of 5 min EEG recorded under RT or RSc condi-
tions. Spectral activity is analysed over 5 min (A). A comparison 
of spectral activity for the segments at the beginning and the end 
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(e.g. time or dose effects) in the early phases of clinical 
drug development.
 In summary, the key factors to consider during the 
planning include, but are not limited to, the suitable type 
of study design, the determination of the sample size and 
the randomisation. In PD studies, the investigator must 
address the problem of ‘multiplicity’ of tests resulting 
from a profusion of parameters (i.e. inferential statistical 
statements) to which a statistical comparison is applied. 
Further, the computation of a large number of statistical 
tests in a given sample may lead to false conclusions and 
must be used carefully  [72] . In a paper published in 1987, 
Abt  [73] distinguishes three levels of statistical approach 
based on probability computations: exploratory, descrip-
tive and confirmatory statistical analyses. The descrip-
tive data analysis suggests inspection of changes by study-
ing the pattern of descriptive p values assessed for all 
pairwise tests for differences in time or treatment. This 
approach is particularly useful for the evaluation of topo-
graphical changes  [74] . Valid alternatives to this method 
include randomisation and non-parametric permutation 
analyses, which are used in brain imaging studies  [75, 76] , 
including EEG source imaging.
 Sources of multiplicity are several variables, time 
points and locations of measurement/observation, and 
comparisons of more than two treatments or different 
galenic formulations. Moreover, pharmaco-EEG profiles 
may also be examined in relation to behavioural changes 
assessed with rating scales, neuropsychological evalua-
tions and computerised cognitive tests.
Ⓒ
Ⓔ
10 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Recording duration (min)
Ⓓ
 Fig. 2. Processing of 15 min EEG recorded under RSc. The variations in spectral activity can be analysed over 
15 min (C) or over consecutive segments (D). A comparison of spectral activity for segments of 3 min at the 
beginning, middle and end of the recording can be applied to capture time-dependent changes (E). 




 Fig. 3. Processing of 10 min EEG recorded under RSco. During the recording session, the subject alternates be-
tween states with eyes open and closed every 60 s. The spectral activity is analysed over the 5 segments corre-
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 Whilst univariate models generally compare individ-
ual variables of between-group or within-subject datas-
ets, multivariate statistics assess multiple factors to create 
discriminants. Some methods utilise linear combina-
tions of EEG measures with other clinical, cognitive and 
affective ratings (neurometric analysis  [77] ). Methods 
based on EEG measures alone are less well developed but 
show future promise  [78] , and this field is advancing rap-
idly, driven mainly by the use of such techniques in func-
tional MRI (fMRI).
 Finally, it should be noted that careful modelling and 
precise correlation with independent parameters, such as 
PK factors, hormonal profile or metabolic status, are often 
needed to determine the particular electrophysiological 
change induced by a neuroactive drug, due to the inherent 
non-specificity of the electrophysiological effects  [79] .
 Due to the complexity of most statistical analyses re-
quired for the evaluation of pharmaco-EEG studies, the 
assistance of an experienced statistician is highly recom-
mended.
 Use of Normative Databases 
 While not always available, when appropriate norma-
tive data exist  [80] , the data collected should be subjected 
to comparisons (e.g. z-transformation) with a normative 
data sample. The power spectrum of the EEG is extreme-
ly stable and highly replicable, distinctive for each brain 
region in a healthy, normally functioning individual, and 
is generally independent of cultural, ethnic or racial fac-
tors. Therefore, this predictable, known power spectrum 
can be used as a normative baseline that specifies the ex-
pected electrical activity of the healthy, normally func-
tioning human brain across the human lifespan. Devia-
tions from these norms can be described as standard 
scores, providing a reliable and objective metric for ab-
normalities of brain electrical activity  [81–83] .
 Pharmaco-EEG – Advanced Topics 
 EEG Source Localisation 
 The ability to display the time course and localisation 
of brain activity based on extracranial measurements re-
quires a mathematical solution to the inverse problem for 
the computation of images of electric neuronal activity 
based on the EEG signals recorded from the electrodes. 
In general, there is no unique solution to this problem. 
Inverse solutions critically depend on many a priori as-
sumptions, including head models, solution spaces, regu-
larisation parameters, the specific assumption on current 
density distribution and procedures used for statistical 
mapping (like normalisation or log transformation) and 
statistical thresholds. All these factors have a significant 
impact on the results that may vary drastically depending 
on the choices made and it is usually impossible to vali-
date the correctness of the choices independently. Conse-
quently, it is therefore absolutely necessary that all of 
these parameters and choices are fully presented and that 
the implications of the choices are explicitly discussed.
 LORETA (low resolution electromagnetic tomogra-
phy) provides 3-dimensional functional imaging of brain 
electrical activity based on multichannel surface EEG re-
cording without a priori knowledge about the putative 
number of discernible source regions  [84, 85] . It is impor-
tant to notice that a reliable estimation of EEG sources 
depends upon the usage of a sufficient number of elec-
trodes (at least 19) which are equally distributed. The spa-
tial resolution is limited by the distances between elec-
trodes in the input matrix and by the assumption of 
smoothness. LORETA can be used to locate the most 
probable cortical and subcortical sources for different fre-
quency bands, and the time resolution of the EEG data can 
be exploited for functional mapping of brain activities, 
whereby the solution space is restricted to cortical grey 
matter. Finally, LORETA images can also be computed 
relative to normative voxel values, allowing sources to be 
evaluated as the deviation from age-expected norms.
 The empirical validity of LORETA has been estab-
lished in a large number of studies  [86] covering various 
EEG research fields, such as psychiatry  [87, 88] , neurol-
ogy  [89, 90] , neuropsychopharmacology  [91] and sleep 
medicine  [92] . Further, the co-registration of LORETA 
with other neuroimaging methods has shown good cor-
respondence of effects  [93, 94] . More recently, LORETA 
has been used to evaluate interactive functional dynamic 
connectivity in the brain, quantified by coherence and 
phase synchronization  [95] .
 Despite the limitations of inherently low resolution 
and the need for a priori assumptions, source localisation 
techniques represent important advances in the utility of 
QEEG that are a useful addition to other available func-
tional neuroimaging techniques, and EEG-based meth-
ods provide direct information on neuronal activity with 
high temporal but low spatial resolution. In contrast, 
fMRI has high spatial resolution but low temporal resolu-
tion that is confounded by the haemodynamic response 
function. Magneto-encephalography combines high spa-
tial and temporal resolution with a direct measure of ac-
tivity but is less well established and not readily available. 
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sources, whereas EEG is most sensitive to radial sources, 
so the techniques may provide different but complemen-
tary information on brain activity  [96] .
 Cordance 
 Cordance is a QEEG analysis procedure that combines 
complementary information from both absolute and rel-
ative power from the EEG spectrum, as well as informa-
tion from neighbouring electrodes for each scalp elec-
trode  [97] . It has been reported to have a stronger correla-
tion with cerebral perfusion as measured by positron 
emission tomography (PET) than either absolute or rela-
tive power alone  [98] , potentially providing a physiologic 
framework for the interpretation of findings.
 Cordance has been used to assess neurophysiological 
changes and treatment outcomes in major depression 
 [99] and to predict the response of treatments in patients 
with major depressive disorder  [100–102] or bipolar de-
pression  [103] . Across studies of patients with major de-
pressive disorder treated with various antidepressant 
medications, decreases in prefrontal  	 cordance 1 week 
after the start of medication have consistently predicted 
response, with overall accuracy ranging from 72 to 88%. 
Examination of this measure in one randomized, double-
blind, placebo-controlled trial has suggested it may be a 
specific indicator of medication efficacy but not placebo 
efficacy  [104] .
 High-Frequency (  ) EEG Activity 
 Over recent years, there has been considerably in-
creased interest in EEG activities in the frequency do-
main above 40 Hz. Prior to 2007, attempts to extract EEG 
activity in the   band used traditional analysis methods. 
However, in 2007, Whitham et al.  [105] demonstrated 
that a considerable proportion of the   signal extracted in 
this way disappeared with temporary muscle paralysis. 
Subsequently, Yuval-Greenberg et al.  [106]  and Keren et 
al.  [107] showed that most of the power in the widely re-
ported induced broad-band   peak at 200–300 ms after a 
visual stimulus did not originate in the brain and was in 
fact due to extra-ocular muscle activity during micro-
saccades.
 Subsequently, methods have been developed to deal 
with these tonic scalp and neck muscle and extra-ocular 
muscle artefacts, hence enabling the true underlying EEG 
signal to be extracted  [107–109] . These techniques require 
recording specifications that exceed those specified 
above, including in particular:
 • Increased sampling rate (2–5 kHz) 
 • Higher low-pass filter cut-off (500–1,000 Hz) 
 • Improved amplitude resolution (0.1   V or below) 
 • Additional EOG electrodes to record fully the extra-
ocular muscle activity 
 • Additional electrodes to record exogenous noise (e.g. 
power-line noise) for regression-based artefact reduc-
tion 
 Enhanced signal processing techniques are also needed, 
such as: 
 • Shorter epoch lengths (typically 512 or 256 ms) to 
maintain the stationarity assumption of the FFT 
 • ICA- or regression-based methods for removal of ex-
ogenous artefacts (e.g. power-line noise or pick-up 
from computer monitors) that would be removed by 
the low-pass filter in traditional recordings 
 • ICA-, regression- or model-based methods for remov-
al of tonic scalp and neck muscle and extra-ocular 
muscle artefacts. 
 This is an area of research in which techniques are de-
veloping rapidly and there is insufficient evidence at pres-
ent to determine the optimal recording and analysis tech-
niques for high-frequency EEG. However, it is clear that 
the choice of method will quantitatively change the re-
sults. Therefore, in studies including high-frequency 
EEG, full details of the recording specification and anal-
ysis techniques used, especially in relation to the artefacts 
discussed above, must be reported such that other labo-
ratories can replicate, and potentially improve upon, the 
results, so the field can continue to advance.
 In addition, the factor analysis used to define the fre-
quency ranges presented in  table 3 did not include cover-
age of frequencies above 40 Hz. Hence, until a formal fac-
tor analysis is undertaken to include the high   frequency 
range, it is important that studies clearly report the fre-
quency bands that have been used. In the absence of any 
other information, the following empirically chosen fre-
quency ranges are suggested as a starting point for inves-
tigators: 30 to  ! 65 (  1 ), 65 to  ! 90 (  2 ), and 90 to  ! 135 Hz 
(  3 )  [110, 111] .
 EEG Biomarkers and Translational Medicine 
 Within the context of drug discovery, the definitions 
of a biomarker, clinical endpoint and surrogate endpoint 
have been formalised by the Biomarkers Definitions 
Working Group  [112] : A biomarker is ‘a characteristic 
that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention’, 
whereas a surrogate endpoint is ‘a biomarker that is in-
tended to substitute for a clinical endpoint’. Put differ-
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pharmacological response (or biological process) that is 
quantifiable, precise and reproducible. Biomarkers may 
be used to diagnose or stage disease processes or predict 
clinical responses to treatments  [113] . In the future, im-
plementation of panels of relevant biomarkers may well 
transform the process of development of new drugs  [114] .
 In the simplest case, EEG can be used as a PD bio-
marker reflecting brain activity in healthy subjects with-
out reference to a specific therapeutic indication. PK-PD 
modelling can thus be undertaken in different species us-
ing a similar outcome measure, hence enabling cross-
species comparisons of the effects of a drug  [115, 116] .
 While EEG has a long history of evaluation in various 
diseases of the CNS, evidence is only recently accruing of 
its putative validity as a useful and reliable biomarker for 
several therapeutic indications  [14] . Recent reviews have, 
for instance, focussed on promising results indicating the 
relevance of QEEG as a reliable and sensitive biomarker 
in many areas, including:
 • Prediction of antidepressant response  [104] 
 • Early detection of mild cognitive impairment and
Alzheimer’s disease  [117, 118] 
 • Application in major neuropathophysiological disor-
ders  [119] 
 • Characterisation of sleep disturbances in depression 
 [120] 
 • Assessment of vigilance in affective disorders  [121] 
 • As a marker of genetic risk for attention deficit hyper-
activity disorder  [122] 
 • As a biomarker for localizing epileptogenic foci in the 
brain  [123] 
 In addition there is an increasing interest in the use of 
ERP biomarkers for characterisation of, for example, the 
cognitive disturbances in schizophrenia  [124] or clinical 
depression  [125] .
 Another important aspect concerns the translatability 
of pharmaco-EEG signatures for the preclinical screen-
ing and the development of CNS-active compounds. The 
goal of translational medicine applied to QEEG is to 
bring brain research from bench to bed and back. There 
are already several examples of successful contribution of 
preclinical EEG-based models in the discovery of psy-
choactive drugs  [14, 126, 127] . These EEG models in ani-
mals have shown promise in improving the understand-
ing of disease mechanisms and therapeutics (e.g. iden-
tification of central effects at a functional level and 
characterisation of central effects depending on the psy-
choactive class or therapeutic indication) or in studying 
the relationship between animal behaviour and EEG ac-
tivity  [128] . Recent papers have further shown the valid-
ity of EEG as putative translatable biomarker in depres-
sion  [129] and Alzheimer’s disease  [130] .
 The major strength of using EEG in translational 
medicine is that most EEG parameters can be measured 
in a similar way in various animal species and human 
subjects, using broadly similar paradigms, recording 
techniques and signal processing algorithms: these simi-
larities not only reflect face validity but also considerable 
construct validity. As similar QEEG methodology is ap-
plicable in different species, it has the potential to bridge 
the gap between preclinical and clinical research. How-
ever, the lack of reliable translational procedures appli-
cable to both patients and experimental animal models is 
an obstacle for the advancement of basic research, the de-
termination of the translational validity of the technolo-
gy and ultimately the development of new compounds 
 [131] for three main reasons:
 (1) Lack of standardisation of animal EEG methodology 
(e.g. low lead density) 
 (2) Lack of specific guidelines on animal QEEG and phar-
maco-sleep EEG recording 
 (3) Lack of valid animal models for psychiatric diseases. 
 In this context, it becomes crucial that efforts are made 
in the standardisation of experimental conditions and in 
the development of protocols facilitating the comparison 
of data collected in both humans and animals. Such a 
concerted harmonisation would also offer the potential 
to quickly acquire large databases that could be shared 
between research groups and hence enable a fuller study 
and understanding of translatability, including:
 • Equivalence of electrode specifications, positioning 
and montage across species including man 
 • Equivalence of preclinical and clinical paradigms, 
such as vigilance control for example 
 • Equivalence of spectral bands in different species 
(both numerically and in terms of species physiology) 
 • Differences between human scalp EEG recordings and 
preclinical cortical recordings (including understand-
ing differences between gyrencephalics and lissence-
phalics) 
 • Equivalence and differences of underlying neurologi-
cal processes and drug effects in different species and 
strains (from mice to primates) 
 Specific guidelines for preclinical, animal pharmaco-
EEG recording and analysis are in preparation for publi-
cation by IPEG. Together with the present guidelines for 
studies in man, these will address several of the above is-
sues and hence should further contribute to optimisation 
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 Conclusion 
 QEEG and related methods have the potential to offer 
reliable biomarkers and will, in view of the recent devel-
opments in QEEG technology, play an increasingly im-
portant role in all phases of drug development. The eval-
uation and quantification of drug effects in pharmaco-
EEG, sleep and EP/ERP studies provide a set of methods 
to capture the therapeutic benefits and the potential ad-
verse effects that a drug induces in diverse patient popu-
lations. By combining various methods and their respec-
tive strengths, it is reasonable to argue that they will pro-
vide a more complete characterisation of the spectrum of 
pharmacologic CNS responses  [132] .
 In this context, it is mandatory to enhance and stan-
dardise methodology and facilitate comparability of data 
across laboratories both in academia and in industry. To 
this end, investigators using pharmaco-EEG are urged to 
refer to and comply with the guidelines presented here 
when designing and conducting studies, and to reference 
the present paper when publishing study results.
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